Alumis’ (ALMS) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Alumis (NASDAQ:ALMS) in a research report report published on Monday,Benzinga reports. Chardan Capital currently has a $38.00 price target on the stock.

Other equities research analysts have also issued research reports about the stock. Citigroup restated an “outperform” rating on shares of Alumis in a research note on Tuesday, January 6th. Wells Fargo & Company increased their price objective on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Stifel Nicolaus assumed coverage on Alumis in a research report on Wednesday, February 25th. They issued a “buy” rating and a $44.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Alumis in a research note on Tuesday, January 6th. Finally, UBS Group reiterated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $38.60.

Alumis Stock Performance

Alumis stock opened at $22.73 on Monday. Alumis has a one year low of $2.76 and a one year high of $30.60. The company has a 50-day simple moving average of $26.34 and a 200-day simple moving average of $14.85. The firm has a market capitalization of $2.89 billion, a P/E ratio of -7.43 and a beta of -0.61.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The firm had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million. Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. As a group, sell-side analysts forecast that Alumis will post -8.51 earnings per share for the current year.

Insider Activity at Alumis

In other news, major shareholder Foresite Capital Management Vi bought 411,764 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were purchased at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James B. Tananbaum bought 411,764 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was purchased at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the transaction, the director directly owned 5,702,536 shares of the company’s stock, valued at $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 1,823,527 shares of company stock valued at $30,999,959. 40.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alumis

Several hedge funds have recently modified their holdings of ALMS. Samsara Biocapital LLC grew its holdings in Alumis by 19.9% during the fourth quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock worth $56,188,000 after acquiring an additional 955,614 shares during the period. Vanguard Group Inc. lifted its holdings in Alumis by 18.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock valued at $16,078,000 after acquiring an additional 625,404 shares during the last quarter. Cormorant Asset Management LP boosted its position in shares of Alumis by 69.3% during the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after purchasing an additional 1,488,200 shares in the last quarter. Trium Capital LLP grew its stake in shares of Alumis by 17.9% in the 3rd quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock worth $12,457,000 after purchasing an additional 474,072 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of Alumis in the 4th quarter worth approximately $23,443,000.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across Q1–Q4 and lifted FY2026/FY2027 outlooks (e.g., FY2026 from ($2.99) to ($2.89); Q1–Q4 tweaks), while maintaining a “Buy” rating and a $25 price target — this reduces projected losses and provides an analyst-backed upside case. HC Wainwright research coverage (summary)
• Positive Sentiment: Chardan Capital assigned a Buy rating, adding an additional institutional endorsement that can attract buyer interest. Alumis Earns Buy Rating from Chardan Capital
• Positive Sentiment: An Oppenheimer analyst is reported to expect the stock to rise, reinforcing bullish sentiment from multiple brokers and likely supporting demand. Oppenheimer bullish note
• Neutral Sentiment: General market coverage (CNN) lists ALMS among tracked stocks; broad news distribution can increase visibility but doesn’t by itself change fundamentals. CNN: Alumis Inc.
• Neutral Sentiment: A news piece with a contrary headline referencing a “pessimistic forecast” appeared, but the underlying broker actions (above) show upward revisions and Buy ratings — treat the conflicting headlines cautiously. HC Wainwright pessimistic forecast article

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.